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Acute Coronary Syndromes:
Is a Unified Management
Strategy Emerging?*
DAVID WATERS, MD, FACC
Hartford and Farmington, Connecticut
Albert Einstein spent the last 30 years of his career in an
unsuccessful attempt to develop a unified field theory encom-
passing all areas of physics. If he had been a cardiologist
working at the end of the 20th century, he might have tried to
develop a unified management strategy for the acute coronary
syndromes. He would have been encouraged to learn that the
pathophysiologic basis of unstable angina and myocardial
infarction are thought to be similar: rupture or erosion of a
vulnerable coronary atherosclerotic plaque with overlying
thrombus formation severe enough to reduce regional coro-
nary flow and cause myocardial ischemia or infarction (1,2).
But how would he have sifted through the evidence related to
treatment? The article by Betriu et al., for the Global Utiliza-
tion of Streptokinase and t-PA [tissue plasminogen activator]
for Occluded Coronary Arteries (GUSTO-I) Investigators (3),
in this issue of the Journal would be as good a place as any to
start.
Angina after thrombolysis for myocardial infarction. In
GUSTO-I, .40,000 patients presenting with ST elevation
within 6 h of the onset of chest pain were randomized to
different forms of thrombolytic therapy. The present study
describes postinfarction angina in GUSTO-I, a complication
that occurred in one-fifth of the patients. Postinfarction angina
greatly increased the risk of reinfarction within 30 days,
particularly when accompanied by transient ST segment ab-
normalities. However, the mortality rate was increased only in
patients whose angina was accompanied by hemodynamic
changes, a combination that fortunately occurred in ,2% of
the GUSTO patients.
Postinfarction angina was a marker of more severe under-
lying coronary disease, as had been shown in older studies
before the thrombolytic era (4). Non-Q wave infarctions now
account for ;50% of all in-hospital myocardial infarctions, but
are greatly underrepresented in GUSTO-I because the selec-
tion criteria included ST elevation. Non-Q wave infarction has
previously been shown (4) to be a marker for postinfarction
angina and reinfarction.
What should these findings from GUSTO-I teach us about
treatment? 1) As shown in Table 4 of the present study, the
time from the onset of postinfarction angina to reinfarction
was very short. Treatment instituted at this point, whether
medical or revascularization, might have an effect on mortality,
but is too late to prevent reinfarction. 2) Treating all patients
prophylactically for postinfarction ischemia will be inefficient,
because four patients will be treated unnecessarily for every
one who will develop symptoms. 3) Intravenous heparin use for
a longer duration was associated with less postinfarction
angina. Platelet glycoprotein IIb/IIIa inhibitors and hirudins
may prove to have a profound impact on the incidence of
postinfarction angina.
Currently, the best approach to postinfarction angina after
thrombolytic therapy appears to be to avoid the problem
altogether, by opting for primary angioplasty instead of throm-
bolysis. Primary angioplasty not only leads to higher patency
rates in the culprit artery, but also permits early identification
of the patient with precarious coronary anatomy who is at high
risk for ischemia and reinfarction. Unfortunately, within the
first few hours after the onset of symptoms, most patients with
a Q wave myocardial infarction will not be in the care of an
interventional cardiologist whose experience meets American
Heart Association/American College of Cardiology guidelines
(5).
Postinfarction ischemia. Although the GUSTO-I Investi-
gators use the term ischemia, they note in their discussion that
their study did not address the issue of silent ischemia.
Postinfarction ischemia detected by Holter monitoring has
been shown (6) to be a strong risk factor, irrespective of
whether the patient received thrombolytic therapy. The asymp-
tomatic patients in GUSTO-I may have had even better
outcomes if those with silent ischemia were excluded.
Postinfarction patients usually undergo some form of a
stress test, and those with myocardial ischemia are considered
for revascularization, particularly if other high risk markers are
present. This approach has recently been validated by the
findings of the Danish Trial in Acute Myocardial Infarction
(DANAMI) (7), where 1,008 patients with inducible myocar-
dial ischemia after thrombolytic therapy for myocardial infarc-
tion were randomized to early angiography, with revascular-
ization where possible, or to conservative treatment. After 2.4
years of follow-up, the invasive strategy was associated with a
lower incidence of reinfarction (5.6% vs. 10.5%, p 5 0.0038)
and admission for unstable angina (17.9% vs. 29.5%, p ,
0.00001).
If an invasive approach improves outcomes after thrombo-
lytic therapy in patients with myocardial ischemia, might it not
do so in patients without ischemia as well? As summarized by
Michels and Yusuf (8), an overview of the relevant trials shows
that neither early nor delayed angioplasty adds benefit when
applied routinely after thrombolytic therapy.
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Non-Q wave myocardial infarction. Patients with a non-Q
wave myocardial infarction usually undergo coronary arteriog-
raphy during the hospital period, with a view to revasculariza-
tion because their risk of reinfarction over the ensuing year is
high. This approach was compared with a conservative strategy
of noninvasive risk stratification in the Veterans Affairs Non-Q
Wave Infarction Strategies In-Hospital (VANQWISH) Trial
(9). A total of 920 patients were enrolled. Conservatively
managed patients were referred for angiography only if testing
revealed high risk features, such as .2-mm ST depression on
exercise testing or multiple redistribution defects on their
stress nuclear images. Most patients in the invasive group, and
very few in the conservative group, underwent coronary bypass
surgery or angioplasty. All patients were followed up for 1 year.
The primary end point, death or nonfatal reinfarction,
occurred during the hospital period in 7.8% of the invasive
group and 3.3% of the conservative group (p 5 0.01); at 30
days these rates were 10.4% and 5.7%, respectively (p 5 0.03),
and at 1 year they were 24.0% and 18.6%, respectively. We can
conclude from the VANQWISH study not only that a conser-
vative strategy is at least as good as an invasive strategy in the
management of patients with a non-Q wave infarction, but that
the event rate for this syndrome remains very high, despite
current therapy. As with the situation after thrombolytic
therapy, it appears wise to restrict revascularization to patients
with evidence of ischemia; and better thrombin inhibitors or
antiplatelet drugs, perhaps given for longer periods, might
reduce the high event rate over the ensuing year.
Unstable angina. The problem of recurrent coronary
events due to continuing instability of the culprit lesion has
recently been well characterized in unstable angina. Investiga-
tors from St. George’s Hospital in London described a series of
85 consecutive patients with unstable angina whose symptoms
stabilized on medical treatment, and who were scheduled for
elective coronary angioplasty (10). During an average wait of 8
months for the procedure, 1 patient died and 25 had nonfatal
coronary events; these events, 4 myocardial infarctions and 21
recurrences of unstable angina, were usually related to docu-
mented progression of the culprit lesion.
Most cardiologists believe that early angioplasty would
reduce this high event rate, but clinical trial results to substan-
tiate this belief are lacking. In the Thrombolysis in Myocardial
Ischemia (TIMI) IIIB trial (11), where two-thirds of patients
had unstable angina and one-third had a non-Q wave infarc-
tion, an early invasive strategy did not reduce the rate of death
or infarction at 6 weeks compared with a strategy of reserving
coronary angiography for patients with recurrent symptoms or
inducible ischemia.
A unified management strategy. Einstein said that all
science requires faith in the inner harmony of the world, but
his ordered world of theoretical physics was not subject to the
biologic vagaries of clinical cardiology. A formulaic approach
to the treatment of acute coronary syndromes is not possible,
but the following conclusions seem clear. Patients with acute
coronary syndromes are at increased risk for subsequent
coronary events if spontaneous or stress-induced myocardial
ischemia complicates their course. Patients with myocardial
ischemia have been shown to benefit from revascularization.
The GUSTO-I population teaches us that prevention is the
best approach to ischemia after thrombolytic therapy, because
the interval between the onset of ischemic symptoms and
reinfarction is often very short. Newer antiplatelet and anti-
thrombotic agents are likely to prove helpful in this regard. A
strategy of coronary angiography and revascularization when-
ever possible should not be applied indiscriminantly to all
patients with acute coronary syndromes. The presence of
ischemia, either spontaneous or induced with low levels of
stress, should be a prime criterion for selecting patients for an
invasive approach.
Einstein’s statement in an entirely different context seems
curiously relevant: “Perfection of means and confusion of goals
seem—in my opinion—to characterize our age.”
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